Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Stock Information for Arlington Asset Investment Corp Class A (new)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arlington Asset Investment Corp Class A (new)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune to Participate at Two Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.